Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


The LIXI study aimed to determine whether administration of lixisenatide, a Glucagon Like Peptide-1 receptor agonist could improve glycaemic control when added to insulin therapy in people with type 1 diabetes.


Open-label, non-randomised dose-finding pilot stud, followed by a randomised, placebo-controlled, double-blind, cross over trial.


Lixisenatide suppressed glucagon and reduced postprandial glycaemia without compromising counter-regulatory responses during induced hypoglycaemia. The results were published in 2020.